KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams & Wilkins
Access Rights
info:eu-repo/semantics/closedAccess
DOI
Abstract
Description
Keywords
Journal or Series
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
WoS Q Value
Scopus Q Value
Volume
41
Issue
16
Citation
Lavie, D., Timmerman, J., Sanz, R. G., Kim, W.S., Kim, T. M., Avigdor, A. ... Herrera, A. F. (2023). KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
info:eu-repo/semantics/closedAccess
